

Ioannis Avgerinos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8249801/publications.pdf>

Version: 2024-02-01

16
papers

705
citations

840776

11
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

629
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 173, 278-286.	3.9	182
2	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. <i>Diabetologia</i> , 2022, 65, 1251-1261.	6.3	93
3	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2116-2124.	4.4	79
4	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2255-2263.	4.4	71
5	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108737.	2.8	61
6	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 335-345.	4.4	54
7	Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1857-1868.	4.4	44
8	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 188-193.	4.4	33
9	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 106-114.	4.4	19
10	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2395-2401.	4.4	18
11	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 822-831.	4.4	17
12	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 281-289.	1.9	10
13	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108921.	2.8	10
14	Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. <i>Journal of General Internal Medicine</i> , 2020, , 1.	2.6	7
15	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 2549-2557.	2.4	6
16	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2021, 174, 141.	3.9	1